Cargando…

Genetic Association of Curative and Adverse Reactions to Tyrosine Kinase Inhibitors in Chinese advanced Non-Small Cell Lung Cancer patients

Epidermal growth factor receptor (EGFR) Tyrosine kinase inhibitor (TKI) is an effective targeted therapy for advanced non-small cell lung cancer (NSCLC) but also causes adverse drug reactions (ADRs) e.g., skin rash and diarrhea. SNPs in the EGFR signal pathway, drug metabolism/ transport pathways an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruan, Yunfeng, Jiang, Jie, Guo, Liang, Li, Yan, Huang, Hailiang, Shen, Lu, Luan, Mengqi, Li, Mo, Du, Huihui, Ma, Cheng, He, Lin, Zhang, Xiaoqing, Qin, Shengying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4796893/ https://www.ncbi.nlm.nih.gov/pubmed/26988277 http://dx.doi.org/10.1038/srep23368

Ejemplares similares

Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients
por: Wang, Cong, et al.
Publicado: (2018)

Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors
por: Zhou, F., et al.
Publicado: (2023)

Novel genetic susceptibility loci identified by family based whole exome sequencing in Han Chinese schizophrenia patients
por: Li, Mo, et al.
Publicado: (2020)

Adverse Reaction Profiles Related to Gastrointestinal Bleeding Events Associated with BCR-ABL Tyrosine Kinase Inhibitors
por: Kawada, Kei, et al.
Publicado: (2022)

Renal adverse reactions of tyrosine kinase inhibitors in the treatment of tumours: A Bayesian network meta-analysis
por: Xiong, Ying, et al.
Publicado: (2022)

Functional characterization of the chlorzoxazone 6-hydroxylation activity of human cytochrome P450 2E1 allelic variants in Han Chinese
por: Wang, Ting, et al.
Publicado: (2020)

Functional Characterization of Human CYP2C9 Allelic Variants in COS-7 Cells
por: Du, Huihui, et al.
Publicado: (2016)

Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting System
por: Barbieri, Maria Antonietta, et al.
Publicado: (2023)

Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System
por: Barbieri, Maria Antonietta, et al.
Publicado: (2023)

Discovery of Novel Biomarkers of Therapeutic Responses in Han Chinese Pemetrexed-Based Treated Advanced NSCLC Patients
por: Zhang, Xiaoqing, et al.
Publicado: (2019)

Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia
por: Yoshifuji, Kota, et al.
Publicado: (2022)

A mechanism for localized dynamics-driven activation in Bruton's tyrosine kinase
por: Qiu, Simei, et al.
Publicado: (2021)

Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK
por: Califano, R., et al.
Publicado: (2015)

Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management
por: Shyam Sunder, Sunitha, et al.
Publicado: (2023)

Profiling Receptor Tyrosine Kinase Fusions in Chinese Breast Cancers
por: Tao, Zhonghua, et al.
Publicado: (2021)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects
por: Jing, Shan, et al.
Publicado: (2023)

Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment
por: Kekäle, Meri, et al.
Publicado: (2015)

Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
por: Mohanavelu, Prahathishree, et al.
Publicado: (2021)

Adverse Toxic Effects of Tyrosine Kinase Inhibitors on Non-Target Zebrafish Liver (ZFL) Cells
por: Kološa, Katja, et al.
Publicado: (2023)

Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies
por: Song, Yuqin, et al.
Publicado: (2023)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

Nanomedicine of tyrosine kinase inhibitors
por: Smidova, Veronika, et al.
Publicado: (2021)

Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors
por: Li, Jian, et al.
Publicado: (2018)

A clinical observation of Chinese chronic myelogenous leukemia patients after discontinuation of tyrosine kinase inhibitors
por: Li, Qing, et al.
Publicado: (2016)

Genetic Association of Olanzapine Treatment Response in Han Chinese Schizophrenia Patients
por: Zhou, Wei, et al.
Publicado: (2019)

Pyk2 is a Novel Tau Tyrosine Kinase that is Regulated by the Tyrosine Kinase Fyn
por: Li, Chuanzhou, et al.
Publicado: (2018)

Modulation of β-Catenin Signaling by the Inhibitors of MAP Kinase, Tyrosine Kinase, and PI3-Kinase Pathways
por: Zhang, Wenwen, et al.
Publicado: (2013)

Advances in studies of tyrosine kinase inhibitors and their acquired resistance
por: Jiao, Qinlian, et al.
Publicado: (2018)

Treatment compliance and severe adverse events limit the use of tyrosine kinase inhibitors in refractory thyroid cancer
por: Chrisoulidou, Alexandra, et al.
Publicado: (2015)

Nursing Management and Adverse Events in Thyroid Cancer Treatments with Tyrosine Kinase Inhibitors. A Narrative Review
por: De Leo, Aurora, et al.
Publicado: (2021)

Targeting Spleen Tyrosine Kinase-Bruton's Tyrosine Kinase Axis for Immunologically Mediated Glomerulonephritis
por: Chen, Jin-Shuen, et al.
Publicado: (2014)

Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
por: Labots, Mariette, et al.
Publicado: (2016)

Latest progress in tyrosine kinase inhibitors
por: Pospelova, Tatiana V., et al.
Publicado: (2014)

Tyrosine kinase inhibitors in sarcoma treatment
por: Kyriazoglou, Anastasios, et al.
Publicado: (2022)

The AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma
por: Hsieh, Min-Shu, et al.
Publicado: (2016)

Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors
por: Caocci, Giovanni, et al.
Publicado: (2020)

Cardiovascular Adverse Events and Mitigation Strategies for Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitor Therapy
por: Nodzon, Lisa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4f8r143pou2upeqr441iarr3el